Paul Schimmel is Director at ALNYLAM PHARMACEUTICALS, INC. (ALNY). They have made 33 open-market trades across 5 companies since 2006, most recently 2026-05-27.
CIK 0001236447
26 open-market purchases totalling $10.7M since 2006, against 7 sales. Across 26 scored buys the stock is down 8.4% at ninety days, and 10.7 points behind the S&P over the same stretch.
26 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 38% | 35% | 31% |
| Avg Move | -0.0% | -1.7% | -8.4% |
| Alpha | +0.6% | -1.0% | -10.7% |
| Scored | 26 | 26 | 26 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ATYR | BUY | 2026-05-27 | 2026-05-28 | $0.50 | $50K | -15.1% | +5.8% | -0.3% |
| ATYR | BUY | 2025-10-08 | 2025-10-09 | $0.91 | $1.8M | -3.7% | -26.2% | -30.2% |
| ATYR | BUY | 2024-07-22 | 2024-07-24 | $1.81 | $256K | -6.0% | -5.5% | +67.5% |
| LIFE | BUY | 2023-05-10 | 2023-05-11 | $2.25 | $450K | +6.0% | -4.7% | -16.6% |
| LIFE | BUY | 2021-09-20 | 2021-09-22 | $8.00 | $2.0M | -25.1% | -26.8% | -33.3% |
| LIFE | BUY | 2021-05-18 | 2021-05-20 | $3.98 | $199K | +5.2% | -2.7% | +5.2% |
| LIFE | SELL | 2020-05-20 | 2020-05-22 | $3.64 | $31K | -9.9% | -3.1% | +8.9% |
| LIFE | BUY | 2020-02-10 | 2020-02-11 | $4.25 | $1.1M | +3.7% | -31.9% | +2.0% |
| LIFE | BUY | 2018-11-26 | 2018-11-28 | $0.54 | $159K | -9.8% | -15.7% | -20.9% |
| LIFE | BUY | 2018-08-31 | 2018-09-05 | $0.74 | $32K | -10.7% | -4.8% | -29.8% |
| LIFE | BUY | 2018-08-29 | 2018-08-31 | $0.73 | $176K | -5.3% | +2.0% | -17.8% |
| LIFE | BUY | 2018-05-18 | 2018-05-21 | $1.00 | $150K | +0.0% | +45.5% | -24.6% |
| ALNY | SELL | 2018-03-13 | 2018-03-14 | $150.00 | $4.2M | -2.9% | -29.4% | -25.8% |
| LIFE | BUY | 2017-08-31 | 2017-09-05 | $2.65 | $500K | +27.6% | +96.6% | +34.5% |
| TOCA | BUY | 2017-04-19 | 2017-04-21 | $10.00 | $100K | +23.8% | +21.9% | -23.4% |
| LIFE | BUY | 2016-12-20 | 2016-12-22 | $2.27 | $57K | -2.0% | +20.4% | +40.8% |
| LIFE | BUY | 2016-12-15 | 2016-12-19 | $2.48 | $124K | -4.4% | +44.4% | +64.4% |
| LIFE | BUY | 2016-04-14 | 2016-04-15 | $4.19 | $419K | -9.7% | -27.7% | -36.9% |
| LIFE | BUY | 2016-04-13 | 2016-04-14 | $3.85 | $38K | -8.9% | -28.0% | -36.9% |
| LIFE | BUY | 2016-04-12 | 2016-04-13 | $3.71 | $34K | -1.0% | -27.3% | -31.5% |
| LIFE | BUY | 2016-04-11 | 2016-04-12 | $3.59 | $98K | +6.9% | -26.9% | -30.2% |
| LIFE | BUY | 2016-04-11 | 2016-04-13 | $3.57 | $117K | -1.0% | -27.3% | -31.5% |
| LIFE | BUY | 2016-04-08 | 2016-04-11 | $3.22 | $274K | +8.4% | -18.6% | -26.2% |
| LIFE | BUY | 2016-04-07 | 2016-04-08 | $3.19 | $128K | +17.1% | -3.3% | -18.0% |
| LIFE | BUY | 2016-04-06 | 2016-04-07 | $3.20 | $80K | +17.5% | -0.6% | -13.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| Total |
| $146.2M |
Shares reported on the most recent Form 4, priced at the 2026-05-28 close. 1 holding could not be priced and is excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.